---
---

# 21 U.S.C., USLM ref /us/usc/t21/s387r

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../..//us/usc/t21/ch9/schIX/m__us_usc_t21_s387q.md) | [Next](./../../../../..//us/usc/t21/ch9/schIX/m__us_usc_t21_s387s.md) | [Root of Title](./../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs387r)

## § 387r. Drug products used to treat tobacco dependence

    (a) __In general__ 

    The Secretary shall—

        (1) at the request of the applicant, consider designating products for smoking cessation, including nicotine replacement products as fast track research and approval products within the meaning of [section 356 of this title][/us/usc/t21/s356];

        (2) consider approving the extended use of nicotine replacement products (such as nicotine patches, nicotine gum, and nicotine lozenges) for the treatment of tobacco dependence; and

        (3) review and consider the evidence for additional indications for nicotine replacement products, such as for craving relief or relapse prevention.

    (b) __Report on innovative products__ 

        (1) __In general__ 

        Not later than 3 years after June 22, 2009, the Secretary, after consultation with recognized scientific, medical, and public health experts (including both Federal agencies and nongovernmental entities, the Institute of Medicine of the National Academy of Sciences, and the Society for Research on Nicotine and Tobacco), shall submit to the Congress a report that examines how best to regulate, promote, and encourage the development of innovative products and treatments (including nicotine-based and non-nicotine-based products and treatments) to better achieve, in a manner that best protects and promotes the public health—

            (A) total abstinence from tobacco use;

            (B) reductions in consumption of tobacco; and

            (C) reductions in the harm associated with continued tobacco use.

        (2) __Recommendations__ 

            The report under paragraph (1) shall include the recommendations of the Secretary on how the Food and Drug Administration should coordinate and facilitate the exchange of information on such innovative products and treatments among relevant offices and centers within the Administration and within the National Institutes of Health, the Centers for Disease Control and Prevention, and other relevant agencies.

([June 25, 1938, ch. 675, § 918][/us/act/1938-06-25/ch675/s918], as added [Pub. L. 111–31, div. A, title I, § 101(b)(3)][/us/pl/111/31/s101/b/3], June 22, 2009, [123 Stat. 1825][/us/stat/123/1825].)

 __Modification of Deadlines for Secretarial Action__ 

    With respect to any time periods specified in an amendment by div. A of [Pub. L. 111–31][/us/pl/111/31] that begin on June 22, 2009, within which the Secretary of Health and Human Services is required to carry out and complete specified activities, with certain limitations, the calculation of such time periods shall commence on the first day of the first fiscal quarter following the initial 2 consecutive fiscal quarters of fiscal year 2010 for which the Secretary has collected fees under [section 387s of this title][/us/usc/t21/s387s], and the Secretary may extend or reduce the duration of one or more such time periods, except that no such period shall be extended for more than 90 days, see [section 6 of Pub. L. 111–31][/us/pl/111/31/s6], set out as a note under [section 387 of this title][/us/usc/t21/s387].

----------

[Previous](./../../../../..//us/usc/t21/ch9/schIX/m__us_usc_t21_s387q.md) | [Next](./../../../../..//us/usc/t21/ch9/schIX/m__us_usc_t21_s387s.md) | [Root of Title](./../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs387r)

----------
----------

[/us/usc/t21/s356]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs356
[/us/act/1938-06-25/ch675/s918]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675%2Fs918
[/us/pl/111/31/s101/b/3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F31%2Fs101%2Fb%2F3
[/us/stat/123/1825]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F123%2F1825
[/us/pl/111/31]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F31
[/us/usc/t21/s387s]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs387s
[/us/pl/111/31/s6]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F31%2Fs6
[/us/usc/t21/s387]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs387


